SCHEDULE: Vanguard Group Adjusts Ultragenyx Ownership Reporting

The Vanguard Group reported zero beneficial ownership in Ultragenyx Pharmaceutical Inc. common stock following an internal corporate realignment.

Summary

• The Vanguard Group filed an Amendment No. 10 to its Schedule 13G for Ultragenyx Pharmaceutical Inc.
• The filing indicates that The Vanguard Group now beneficially owns 0 shares, representing 0% of Ultragenyx Pharmaceutical Inc.'s common stock.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for Ultragenyx Pharmaceutical Inc., as the change in beneficial ownership reporting by The Vanguard Group is due to an internal corporate realignment rather than a direct investment decision related to the issuer's performance or prospects.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Ultragenyx Pharmaceutical Inc.'s future performance or operations.

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment.
• In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.
• Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that institutional ownership changes, especially from major asset managers like Vanguard, can sometimes signal shifts in investment strategy or portfolio rebalancing. However, in this specific case, the change is explicitly attributed to an internal corporate realignment within Vanguard rather than a fundamental change in investment thesis regarding Ultragenyx Pharmaceutical Inc.

Stakeholder Impact

• Shareholders of Ultragenyx Pharmaceutical Inc. will observe a change in the reported beneficial ownership by The Vanguard Group, though the underlying investment by Vanguard's various funds and divisions is likely to continue, just reported under different entities. No direct impact on employees, customers, suppliers, or creditors is indicated by this filing.

Next Steps

• Vanguard's subsidiaries or business divisions will report beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538.

Key Dates

Keywords

Ultragenyx Pharmaceutical, Vanguard Group, Schedule 13G, beneficial ownership, institutional ownership, UGNX